Loading
Generic imatinib and abiraterone can cost patients hundreds of dollars a month through insurance yet be sold at cost plus a fixed markup by transparent pharmacies; making that the default channel for oral cancer generics would save patients and plans money.
Mark Cuban Cost Plus Drug Company publishes its acquisition cost, a 15% markup, a pharmacy fee and shipping for each drug, including oncology generics such as imatinib, abiraterone, anastrozole, letrozole and capecitabine. Prices are often far below insurance copays on specialty tiers. Payers can add such pharmacies to networks, waive the deductible for them, or use their prices as a reference in formulary tiering.
Shares Oncology drug pricing and price transparency, Financial toxicity, Prices and value.
Shares Letrozole (and other aromatase inhibitors), Tamoxifen, Imatinib, Prices and value.
Shares Oncology drug pricing and price transparency, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Oncology drug pricing and price transparency, Financial toxicity, Imatinib, Prices and value.
Shares No incentive to repurpose cheap drugs, Prices and value.
Shares Letrozole (and other aromatase inhibitors), Tamoxifen.